Sun Pharma, a prominent Mumbai-based drugmaker, reported robust financial results for the third quarter of fiscal year 2026 (Q3FY26), demonstrating significant growth across its various business segments. The company's total sales escalated by 15.1% year-on-year, reaching ₹15,469 crore. Concurrently, total revenue from operations saw a rise of 13.4% year-on-year, touching ₹15,520.5 crore, surpassing the Bloomberg poll's revenue forecast of ₹14,792 crore.

The company's earnings before interest, taxes, depreciation, and amortization (Ebitda) for the quarter stood at ₹4,948.5 crore, marking a substantial increase of 23.4%. This impressive growth also translated into an improved Ebitda margin, which rose to 31.9% from 29.3% in the same period a year ago. This strong financial performance was primarily driven by steady revenue growth in its branded businesses across India and emerging markets, coupled with strong global innovative sales, effectively counteracting a decline in sales of its drug, Revlimid.

Kirti Ganorkar, the managing director, highlighted the well-rounded growth across all businesses, specifically crediting the Branded businesses in India, Emerging Markets, and Global Innovative Medicines. He also noted the expansion of Sun Pharma's innovative product portfolio with the recent launch of Unloxcyt in the US and the introduction of Ilumya in India, reinforcing the company's commitment to novel drug offerings.

Regionally, Sun Pharma's sales performance showed varied dynamics. US generic sales recorded a marginal increase of 0.6% year-on-year, reaching $477 million. Overall US sales constituted approximately 27.5% of the total consolidated sales. Global innovative medicine sales were strong at $423 million for Q3FY26, which included a milestone income of $55 million. Excluding this milestone income, global innovative medicine sales saw a 13.2% increase and accounted for 21.2% of total sales. Notably, for the first time in the September quarter, Sun Pharma's innovative sales outpaced generic sales in the US, indicating a strategic shift towards novel drugs.

In its home market, India, Sun Pharma's sales surged by 16.2% to ₹4,999 crore, successfully outpacing the growth of the overall Indian pharmaceutical market. India sales represented 32.3% of the company's total sales. Furthermore, the company's market share in India improved from 8.1% to 8.4%, according to Pharmarack's MAT December 2025 report.

Looking ahead, Sun Pharma has received approval from the central regulator to launch semaglutide for weight management and intends to launch it once its patent expires in March. However, the company faces uncertainty regarding the potential impact of the most-favoured nation (MFN) drug pricing norms being enforced in the US. These norms, part of the Trump administration’s initiative to localize healthcare and reduce costs for Americans, require drug manufacturers to match the lowest price offered for a drug in other developed countries. Sun Pharma has yet to announce any potential impact from these regulations.

On the stock market, Sun Pharma's share price concluded trading on Friday at ₹1,595.00 on the NSE, experiencing a marginal increase of 0.36%.